Cim Investment Management Inc. Lowers Position in Bristol Myers Squibb Company $BMY

Cim Investment Management Inc. cut its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 50.6% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,461 shares of the biopharmaceutical company’s stock after selling 14,810 shares during the quarter. Cim Investment Management Inc.’s holdings in Bristol Myers Squibb were worth $652,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BMY. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth about $25,000. Harbor Capital Advisors Inc. lifted its position in Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 313 shares during the period. JPL Wealth Management LLC bought a new stake in Bristol Myers Squibb during the third quarter worth about $36,000. Total Investment Management Inc. purchased a new stake in Bristol Myers Squibb in the second quarter worth about $38,000. Finally, Twin Peaks Wealth Advisors LLC bought a new position in shares of Bristol Myers Squibb during the second quarter valued at approximately $40,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BMY has been the subject of several recent research reports. Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and lifted their target price for the company from $52.00 to $61.00 in a report on Monday, December 15th. HSBC lifted their price objective on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research note on Tuesday. Scotiabank reissued a “sector perform” rating and issued a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Royal Bank Of Canada started coverage on Bristol Myers Squibb in a report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price target for the company. Finally, Citigroup lifted their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Nine equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and a consensus price target of $61.41.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: HSBC raised its price target on BMY from $53 to $60 and kept a “hold” rating, signaling improved near-term analyst sentiment (though the new PT offers only ~0.5% upside from current levels). Benzinga
• Positive Sentiment: BMY reported that its investigational candidate BMS-986278 advanced through a key heart safety study (Phase 1 update), reducing development risk for that program and supporting pipeline value upside if subsequent data are favorable. TipRanks: BMS-986278 Update
• Neutral Sentiment: Zacks published a piece framing BMY as a strong value stock based on style scores and valuation metrics — a reminder that some investors are viewing BMY as a defensive, income-oriented pick rather than a high-growth biotech. Zacks: Value Stock
• Neutral Sentiment: Recent market commentary notes BMY has slightly outperformed recent market returns, reflecting stability from its commercial portfolio and dividend profile rather than fresh catalysts. Yahoo Finance: Market Performance
• Neutral Sentiment: Analyst comparisons (Pfizer vs. BMY) highlight competition in oncology and pipeline-driven M&A/portfolio moves; these comparisons keep investor focus on relative pipeline strength and strategic deals. Zacks: PFE vs BMY

Bristol Myers Squibb Price Performance

NYSE BMY opened at $59.71 on Wednesday. The stock has a market capitalization of $121.59 billion, a price-to-earnings ratio of 17.31, a PEG ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The business’s fifty day moving average price is $58.47 and its 200-day moving average price is $51.64.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter last year, the firm posted $1.67 earnings per share. The business’s quarterly revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.